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ABSTRACT Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical
features and share pathobiological mechanisms but are often considered distinct disorders. Prospective,
observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global,
prospective observational 3-year study enrolling ∼12000 patients ⩾12 years of age from primary and
specialist clinical practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329).
NOVELTY’s primary objectives are to describe patient characteristics, treatment patterns and disease
burden over time, and to identify phenotypes and molecular endotypes associated with differential
outcomes over time in patients with a diagnosis/suspected diagnosis of asthma and/or COPD. NOVELTY
aims to recruit real-world patients, unlike clinical studies with restrictive inclusion/exclusion criteria.
Data collected at yearly intervals include clinical assessments, spirometry, biospecimens, patient-reported
outcomes (PROs) and healthcare utilisation (HCU). PROs and HCU will also be collected 3-monthly via
internet/telephone. Data will be used to identify phenotypes and endotypes associated with different
trajectories for symptom burden, clinical progression or remission and HCU. Results may allow patient
classification across obstructive lung disease by clinical outcomes and biomarker profile, rather than by
conventional diagnostic labels and severity categories.
NOVELTY will provide a rich data source on obstructive lung disease, to help improve patient outcomes
and aid novel drug development.
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Introduction
Asthma and chronic obstructive pulmonary disease (COPD) afflict a combined total of more than 600
million patients globally [1] and are associated with substantial symptom burden, functional impairment
and mortality [1, 2]. Although they are often viewed as distinct disorders, both are now acknowledged as
heterogeneous and overlapping obstructive lung diseases [3, 4]; an estimated 15–27% of adults with a
diagnosis of asthma or COPD have both diagnoses or features of both [5, 6].
Clear evidence exists that patients may have different trajectories in lung function over time [7, 8], with potential
genetic and clinical contributors [9], while exacerbation-prone populations have been identified in asthma and
COPD [10, 11]. Variations in environmental exposure, disease management and access to care and medicines
also contribute to the considerable disparities seen in asthma outcomes worldwide [12]. To improve
outcomes, a greater understanding of patient phenotypes (observable characteristics) and endotypes
(distinct molecularly defined functional or pathobiological pathways that may be associated with distinct
treatment responses) [13] is required across obstructive lung disease and over time (box 1). Biomarkers
(defined characteristics measured as an indicator of normal biologic processes, pathogenic processes or
responses to an intervention [14]) are key to understanding phenotypes and distinguishing their underlying
molecular endotypes, which may help define future therapeutic strategies for distinct patient subgroups.
Although clinical trials are key to defining clinical efficacy and safety of treatments and informing guidelines,
regulatory studies exclude up to approximately 95% of patients with asthma or COPD seen in clinical practice [16].
Many studies are limited to patients with only asthma or COPD, with precisely defined disease, and good
inhaler technique and adherence, and comorbidities are often an exclusion criterion despite their impact on
disease burden and patient outcomes [17–19]. The ecology of care can differ considerably from that in clinical
practice [18]. Together, this limits the generalisability of data on which clinical guidelines are largely based.
Recent observational studies provide valuable insights into patient characteristics and associated genetics,
biomarkers and phenotypes [4, 20–25]. However, these generally focus on either asthma or COPD [26, 27],
are restricted to distinct geographies [28, 29], or study more severe or intensively monitored and treated
disease. They may be cross-sectional, so patients following different temporal trajectories [7, 8] may be
grouped together. Increasing demand exists for longitudinal observational data in patients across
Box 1. Definitions [13–15]
Phenotype: The observable characteristics of a disease, such as morphology, development, biochemical
or physiological properties, or behaviour.
For example, the population with an identified phenotype of obstructive lung disease may share a
cluster of clinical, functional and/or inflammatory features, without any implication of a common
underlying mechanism.
Endotype: A subtype of disease, defined functionally and pathologically by a distinct molecular mechanism
or by distinct treatment responses.
For example, among patients with obstructive lung disease, there are likely to be several specific
endotypes associated with divergent underlying molecular causes, and with distinct treatment
responses. These endotypes may or may not align with clinical or inflammatory phenotypes identified
from studies limited to asthma or to COPD.
Biomarker: A defined characteristic measured as an indicator of normal biologic processes, pathogenic
processes or response to an intervention.
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obstructive lung disease, including those with comorbidities and from diverse clinical settings, to
understand underlying mechanisms.
NOVELTY, a NOVEL observational longiTudinal studY in patients with a diagnosis or suspected diagnosis
of asthma and/or COPD, is a large, global, prospective, 3-year cohort study (www.clinicaltrials.gov,
NCT02760329; study protocol is available at https://astrazenecagrouptrials.pharmacm.com). Here, we
describe the NOVELTY study design and its anticipated outcomes.
Methods
Study design
In NOVELTY, a prospective longitudinal cohort study, patients with a physician diagnosis or suspected
diagnosis of asthma and/or COPD will be recruited from clinical practices over 1.5 years, with recruitment
stratified by diagnostic label and physician-assessed severity (mild, moderate, severe). Data will be recorded
by the treating healthcare professional (HCP) using study-specific electronic case report forms (eCRFs) at
yearly visits for 3 years, and by patients every 3 months and in conjunction with yearly visits (figure 1).
Countries participating are Argentina, Australia, Brazil, Canada, mainland China, Colombia, Denmark, France,
Germany, Italy, Japan, Mexico, the Netherlands, Norway, South Korea, Spain, Sweden, the UK and the USA.
A range of physicians, including primary care physicians, pulmonologists and allergists, will enrol patients
from community and hospital outpatient settings to create a study population drawn from a wide range of
asthma and/or COPD severities.
NOVELTY: a NOVEL observational longiTudinal studY
~12 000 patients ≥12 years of age, from primary and specialist clinical practices in 19 countries
Diagnosis or suspected diagnosis of asthma and/or COPD
≥95% of such patients in clinical practice should be eligible 
Yearly data captured in eCRFs (plus EMR data collected in some countries),
3-month data collected from patient by web-based platform or telephone
Primary study objectives
Describe patient characteristics, treatment patterns and burden of illness over time
Using network analysis techniques, identify phenotypes and endotypes associated with differential
  outcomes for symptom burden, clinical evolution and HCU over time
Baseline data collected at clinical 
practice
  Demographics
  Characteristics
  Asthma/COPD information
  Spirometry
  Exacerbations
  Risk factors
  Impact on daily activity and HRQoL
    (PROs)
  Treatment(s) during previous 12
    months
  HCU during previous 12 months
  Biomarkers and exploratory genetic
    research (optional)
Day 0Annual visits Year 1 Year 2 Year 3
Large population
Diverse asthma/COPD 
spectrum
Wide geographical coverage
Characteristics of the 
research framework [18]
Observational design
Long follow-up during 
usual care
Broad range of data collected,
including PROs and 
biomarkers
Non-hypothesis-based 
analysis
3-month
follow up
3-monthly follow ups
  Asthma/COPD information
  Treatments
  Exercerbations
  Impact on daily activity
    and HRQoL (PROs)
Annual visits to clinical practice
  Demographics - occupational only
  Characteristics
  Asthma/COPD information
  Spirometry
  Exacerbations
  Risk factors
  Impact on daily activity and HRQoL
    (PROs)
  Treatment(s) during previous 
    12 months
  HCU during previous 12 months
  Biomarkers (optional) 
FIGURE 1 NOVELTY study design. COPD: chronic obstructive pulmonary disease; eCRF: electronic case report form; EMR: electronic medical
record; HCU: healthcare utilisation; HRQoL: health-related quality of life; PRO: patient-reported outcome.
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Study objectives
The primary objectives of NOVELTY:
1) To describe patient characteristics, treatment patterns and burden of illness over time in patients with
a diagnosis or suspected diagnosis of asthma and/or COPD.
2) To identify clinical phenotypes and molecular endotypes based on biomarkers and/or clinical
parameters that are associated with differential outcomes for symptom burden, clinical evolution and
healthcare utilisation (HCU) over time.
The longitudinal analysis will thus focus on differential outcomes in three main domains: symptoms
(reflecting burden on patients), clinical evolution (reflecting progression or remission in clinical severity,
including lung function) and HCU (reflecting the impact on the health system).
Secondary objectives include comparing patients’ diagnostic labels and physician-assessed severity with
definitions in existing guidelines and with phenotypic groupings. Patient characteristics, symptom burden,
health-related quality of life (HRQoL), exacerbation rates and clinical evolution (i.e. clinical progression or
remission) will be described in relation to phenotypes and endotypes for subpopulations including patients
with recent-onset disease and those with mild or severe disease at enrolment. Specified biomarkers will
also be examined to evaluate their stability over time, factors affecting their variability, and their
relationships with clinical features and phenotypes.
Other, more exploratory, objectives include descriptions of all-cause and respiratory-related HCU,
patient-reported outcomes (PROs; impact on daily activity and HRQoL), and patterns of exacerbations and
respiratory infections and their relationship with clinical outcomes. An analysis is planned to assess the
adequacy of electronic medical records (EMRs) for obtaining characteristics, clinical progress, and
treatment of patients with obstructive lung disease in countries with suitable EMRs (identified from a
previous feasibility study conducted in 11 target countries [30]), by comparing them with data collected by
NOVELTY eCRFs and PROs.
Patients
Patients will be enrolled from active primary and specialist clinical practices. Patients must have a
diagnosis, or a clinically suspected diagnosis, of asthma and/or COPD according to the treating physician;
intentionally, no diagnostic criteria are specified. Other inclusion criteria are provision of informed
consent (with legal guardian consent for adolescent patients), and age ⩾12 years, although in most
countries only patients ⩾18 years of age can be feasibly included. HCPs will be encouraged to include
patients with recently diagnosed disease (i.e. within 2–5 years before enrolment).
Exclusion criteria are few: participation in an interventional respiratory clinical trial within 12 months
prior to NOVELTY enrolment, patients unlikely to complete 3 years of follow up, and patients whose
primary respiratory diagnosis (the condition causing most of their respiratory symptoms) is not asthma or
COPD. However, co-diagnoses of other respiratory diseases such as bronchiectasis or interstitial lung
disease will be accepted. Patients who have received an allogeneic bone marrow transplant or recent whole
blood transfusion will be excluded from exploratory genetic research.
Study procedures
Patients will be invited to participate in relation to a routine clinical visit and, once consent is obtained,
baseline data will be collected. Patients enrolled during an exacerbation will have baseline data collected
6 weeks later. Patients will have yearly (±3 months) visits with follow-up data collected by their HCP for
3 years or until study discontinuation, whichever comes first. Patients will also complete questionnaires
every 3 months (or up to 21 days later than the target date), by a web-based platform or telephone.
Patients will receive standard medical care as determined by their physician; no experimental intervention
or treatment will be given as part of NOVELTY, and patients will be withdrawn if they enter an
interventional trial. Most study procedures (such as history, medications, questionnaires, PROs and
optional investigations such as allergy testing and imaging) will be conducted according to the patient’s
usual standard of care, as per local guidelines. The exceptions are the performance of spirometry, the
measurement of fractional exhaled nitric oxide, and the collection, storage and shipment of biosamples,
which will be performed in accordance with standardised procedures (see online supplement).
The study will be performed in accordance with ethical principles consistent with the Declaration of
Helsinki, International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use and Good Clinical Practice. In each country, the study protocol has been
approved by the appropriate Institutional Review Board or Independent Ethics Committee.
Data collection
The variables to be measured are listed in tables 1–3.
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Data will primarily be collected via eCRFs completed yearly by the treating HCP, and PROs via patient
questionnaires every 3 months (with relevant translations). These will provide a consistently collected set
of variables aligned to NOVELTY objectives.
The feasibility study revealed that many data required for NOVELTY were not consistently recorded in
EMRs [30], necessitating the study-specific eCRF.
Spirometry will be performed by trained site personnel. For sites with suitable spirometers, data will be
recorded in the eCRF. For other sites, spirometers (ERT FlowScreen®, ERT, Philadelphia, PA, USA), which
meet European Respiratory Society/American Thoracic Society standards [31], will be provided and data
collected centrally (centralised over-read performed at baseline only). For predicted values, reference
equations from the 2012 Global Lung Function Initiative [32] will be used. Reversibility of airway
obstruction will be assessed following withholding of bronchodilators: pre- and post-bronchodilator forced
expiratory volume over 1 s and forced vital capacity will be measured immediately before, and ⩾15 min
after, a bronchodilator is given. Fractional exhaled nitric oxide will be measured at baseline using Niox
Vero devices (Circassia Pharmaceuticals Inc., Morrisville, NC, USA).
PROs will be recorded after the yearly clinic visits and every 3 months (tables 2 and 3). While most
respiratory symptom tools are validated for only asthma or COPD, a distinctive feature of NOVELTY is
that the same PROs will be administered to the whole study population, irrespective of diagnosis. The
chronic airways assessment test (CAAT), a modified version of the COPD assessment test (CAT) [33], will
be used with permission of the copyright holder (GlaxoSmithKline, Brentford, UK), with reference to
COPD replaced with “your pulmonary disease”. As part of CAAT validation, a subset of patients with
COPD will also complete the CAT. Generic information on respiratory symptoms will be collected,
modelled on guidelines for asthma symptom control, but without referring to asthma. In addition to the
above PROs, patients with asthma will complete the Asthma Control Test [34]. The CAPTURE tool (COPD
Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk) [35] will
also be evaluated in NOVELTY.
Data on medications, comorbidities, exacerbations and HCU will be recorded in the eCRF, and
information on medications, exacerbations and HCU will also be collected from patients. Patient-reported
adherence will be compared with prescribing data. Information collected on comorbidities includes type,
duration and ongoing status.
TABLE 1 Patient demographics and characteristics to be measured in NOVELTY
Variable Collection#
Baseline Every 3 months Yearly
Physician-reported Patient-reported Patient-reported Physician-reported Patient-reported
Informed consent ✓
Demographics
Age, ethnicity, gender,
socioeconomic status, income
(USA only), insurance status/
payee (USA only), history of
respiratory interventional trials
participation
✓
Occupation ✓ ✓
Characteristics
Height (post-baseline for
adolescents only), weight, BMI,
waist circumference, heart
rate, pregnancy status
✓ ✓
Risk factors for development of
obstructive lung disease
Smoking status and history,
environmental and
occupational exposure to
pollutants, allergens
✓ ✓
BMI: body mass index; NOVELTY: a NOVEL observational longiTudinal studY. #: baseline and yearly data will be collected from healthcare
professionals during clinical visits, while 3-monthly data will be collected directly from the patient via follow up by web-based platform or
telephone, and in conjunction with their yearly clinical visits.
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Investigators will be asked to record in the eCRF any specialised assessments performed during routine
care (e.g. diffusion capacity of the lung for carbon monoxide, fractional exhaled nitric oxide, computed
tomography scans, 6-minute walk distance and blood clinical chemistry), for which results are available.
With patient consent, blood and urine samples will be collected. Blood samples will be used to measure
biomarkers over time, and, with patients’ specific consent, for exploratory genetic research, such as
investigating genomic, transcriptomic and metabolomic variants associated with the disease phenotypes
that may reveal underlying endotypes. Standardised laboratory protocols have been developed for collection,
TABLE 2 Disease-related variables to be measured in NOVELTY
Variable Collection#
Baseline Every 3 months Yearly
Physician-reported Patient-reported Patient-reported Physician-reported Patient-reported
Asthma/COPD information
Physician-reported diagnosis
and severity
✓
Age at diagnosis, personal and
family history of asthma/
COPD and allergies
✓
Comorbidities ✓ ✓
Asthma/COPD complications,
recent respiratory diseases
(e.g. RTI)
✓ ✓ ✓ ✓ ✓
Exacerbations ✓ ✓ ✓ ✓ ✓
Symptom assessments:
CAAT¶, RSQ
✓ ✓ ✓
Symptom assessments: ACT+,
SGRQ
✓ ✓
mMRC dyspnoea score ✓
CAPTURE screening tool ✓
Lung function measurements
(FEV1, FVC, PEF, FEF25–75%,
IC, calculated FEV1/FVC ratio,
calculated FEV1% predicted)§
✓ ✓
Bronchodilator reversibility test ✓
FeNO ✓
Biomarkers (with specific
consent) ƒ
Blood: differential white
blood cell count
✓ ✓
Blood: serum and plasma##
for biomarker, metabolomic
and proteomic analysis
✓ ✓
Blood: DNA and RNA,
for genomic and
transcriptomic analysis
✓
Urine sample ✓
ACT: asthma control test; CAAT: chronic airways assessment test; CAPTURE: COPD Foundation Primary Care Tool for Undiagnosed
Respiratory Disease and Exacerbation Risk; COPD: chronic obstructive pulmonary disease; FEF25–75%: forced expiratory flow at 25–75% of the
forced vital capacity; FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume over 1 s; FVC: forced vital capacity; IC: inspiratory
capacity; mMRC: modified Medical Research Council; NOVELTY: a NOVEL observational longiTudinal studY; PEF: peak expiratory flow; RSQ:
Respiratory Symptoms Questionnaire; RTI: respiratory tract infection; SGRQ: St George’s Respiratory Questionnaire. #: baseline and yearly data
will be collected from healthcare professionals during clinical visits, while 3-monthly data will be collected directly from the patient via follow
up by web-based platform or telephone, and in conjunction with their yearly clinical visits. ¶: the CAAT is a modified form of the validated
COPD assessment test (CAT), which, with consent of the copyright holder (GlaxoSmithKline, Brentford, UK), excludes specific references to
COPD in order to also assess patients without a COPD diagnosis; a small subset of patients with COPD will complete both the CAAT and CAT
at baseline and year 1, to evaluate the equivalence of the two tests. +: only for patients with an asthma diagnosis, for comparison with the
CAAT. §: for sites where spirometers are provided and data collected centrally, quality control/over-read and Best Test Review will be
performed at baseline. ƒ: in Brazil, no samples will be collected; in China and Denmark, only samples for haematology will be collected; in
Italy, no samples for DNA or RNA analysis will be collected; samples will be collected at each yearly visit in Australia, Canada, France,
Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden, the UK and the USA, and at year 1 only in other countries. ##: plasma will not
be collected from adolescent patients.
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handling, storage and shipping of biosamples (see online supplement), and all site staff will be trained in
sample collection and handling. Biosamples will be stored in a central repository and held for batched
analysis (see online supplement). Peripheral blood differential counts will be available for baseline analysis.
In countries selected for EMR analysis, retrospective EMR data may be collected with patient consent, and
will be compared with eCRF data to assess EMRs as a source for NOVELTY and future studies, and to
evaluate if patients in NOVELTY are representative of nonenrolled patients with a similar diagnosis.
Study organisation and governance
NOVELTY is guided by a scientific committee comprising 12 independent physicians, scientists and
statisticians, and seven scientists and economists from the study sponsor. NOVELTY will accept requests
for proposals from study investigators, sponsor scientists and the broader respiratory community for
TABLE 3 Variables relating to the impact of disease, treatment and healthcare utilisation to be collected in NOVELTY
Variable Collection#
Baseline Every 3 months Yearly
Physician-reported Patient-reported Patient-reported Physician-reported Patient-reported
Impact on daily activity and quality
of life
HRQoL
SGRQ ✓ ✓
EQ-5D-5L ✓ ✓ ✓
WPAI ✓ ✓
Treatment(s) during previous
12 months
Asthma/COPD treatments ✓ ✓ ✓ ✓ ✓
Treatment duration and
frequency
✓ ✓ ✓ ✓ ✓
Posology ✓ ✓
Patterns of use and treatment
adherence for asthma/COPD
treatments
✓ ✓ ✓ ✓
Burden of out-of-pocket
asthma/COPD treatment
expenses¶
✓ ✓
Reasons for switching/
interruptions/discontinuations of
each asthma or COPD treatment
✓ ✓ ✓ ✓
Asthma/COPD treatment
satisfaction
✓ ✓ ✓
Concomitant medications ✓ ✓
Healthcare utilisation during
previous 12 months (eCRF) or
previous 3 months (PROs)
Medications, emergency and
nonemergency physician visits
✓ ✓ ✓ ✓ ✓
Respiratory and nonrespiratory
hospitalisations
✓ ✓ ✓ ✓ ✓
Out-of-pocket expenses
(USA only)
✓ ✓
Exacerbations, emergency
department visits,
hospitalisations, days in ICU
✓ ✓ ✓ ✓ ✓
Tests performed during
exacerbations
✓ ✓
COPD: chronic obstructive pulmonary disease; eCRF: electronic case report form; EQ-5D-5L: EuroQol 5 dimensions 5 levels health
questionnaire; HRQoL: health-related quality of life; ICU: intensive care unit; NOVELTY: a NOVEL observational longiTudinal studY; PRO:
patient-reported outcome; SGRQ: St George’s Respiratory Questionnaire; WPAI: work productivity and activity impairment. #: baseline and
yearly data will be collected from healthcare professionals during clinical visits, while 3-monthly data will be collected directly from the
patient via follow up by web-based platform or telephone, and in conjunction with their yearly clinical visits. ¶: patients will be asked to
consider the burden of out-of-pocket expenses in the 12 months prior to visit.
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additional analyses and add-on studies (further information will become available on the NOVELTY
website, http://aznoveltyproject.com). A governance committee of members from the sponsor and the
scientific committee Chairs will be responsible for reviewing proposals.
Sample size calculation
A hypothesis-free approach will be used, focussing on descriptive and exploratory analyses. Therefore, a
power calculation for a specified outcome is not strictly relevant; the large overall sample size was chosen
to support a wide range of analyses, from general scientific questions to regional or subgroup questions,
with sufficient precision. NOVELTY aims to enrol approximately 12000 patients worldwide; it is assumed
that ∼20% of patients with either diagnosis will have both diagnoses [5]. For subgroup analysis of any
binary variable or classification with a frequency of 5–95%, the precision with a sample size of 600 would
be approximately ±4%; with a sample size of 100, the precision would be approximately ±10%. For data
pooled across all countries and severities, the precision would be high even for rarer characteristics
(frequency <5% or >95%).
Statistical analysis
To allow for advances in knowledge and statistical methods during the study, analysis will be based on
four successive Statistical Analysis Plans. The first will cover baseline data analysis; the second will also
include 1-year data and intervening PROs; and the third will include 2-year data and intervening PROs.
The fourth Statistical Analysis Plan will include longitudinal study data and analyses to address primary
objective 2, which relates to identifying factors contributing to differential outcomes in symptoms, clinical
evolution (i.e. clinical progression or remission) and HCU over time. Each Statistical Analysis Plan will
contain prespecified analyses, and will be finalised prior to database lock for the respective dataset.
Data will be summarised for the overall study population and by prespecified subgroups (including
country, demographics, environmental exposures (including tobacco exposure), symptom history,
treatment history, concurrent clinical features, treatment setting, socioeconomic setting and healthcare
access). For patients who leave the study, data will be censored from the time-point that they leave. Yearly
and end-of-study descriptive analyses will be performed for variables in tables 1–3.
Network analysis approaches will be used to identify groups and connections among multiple types and
levels of clinical and biological data [36]. Multivariable analysis will be utilised to identify novel
phenotypes and endotypes. These analyses will employ exploratory, hypothesis-free techniques including
cluster analysis, principal components analysis, data mining, and systems biology analysis. A range of
methods will be used to visualise the networks, such as those described previously [37].
Cluster analyses will be performed for both baseline and time-course data using clinical and biomarker
features. For example, clinical clusters will be identified on the basis of covariates including symptom
burden, features consistent with evolution of clinical severity (worsening or improvement) over time and
HCU. The specific measures to be included in the assessment of clinical progression or remission will be
pre-specified in the fourth Statistical Analysis Plan to allow for new knowledge emerging by then. Based
on current concepts, they may include symptoms, exacerbations, comorbidities (such as obesity and
cardiovascular outcomes), and lung function measures.
Internal and external validation
Internal validation will be sought by splitting the baseline data 2:1 into training and validation sets, with
the sets balanced for obvious confounders such as age, sex, country of origin and physician diagnosis. This
split will be preserved through follow-up years, under the assumption that dropouts should be even across
the two groups. Multivariable analyses will be applied to the training set to generate a series of
parsimonious prediction models, which may include covariates such as occurrence of exacerbations and
other conditions, in relation to clinical outcomes and PROs. Prediction performance will be determined
using the validation set. A similar approach will be taken with biomarkers included. The primary analysis
of phenotypes and endotypes will be based on longitudinal data, so phenotypes identified in baseline
analyses may be superseded by later analyses. The suitability of existing external studies for validation of
NOVELTY findings may be limited by the restriction of most of these studies to patients with diagnostic
labels of either asthma or COPD, or from one or a few countries, and by use of diagnosis-specific clinical
tools and PROs. Because of these differences, external validation of NOVELTY findings may, by necessity,
be limited (initially at least) to prespecified physician-diagnosis groups and specific countries of origin.
Discussion
NOVELTY is an ambitious and global research project aiming to go beyond conventional diagnostic labels
and existing severity classifications in obstructive lung disease, in order to understand underlying
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mechanistic pathways. Asthma and COPD are among the most studied chronic diseases but progress in
finding new, more effective treatments has been slow and disappointing compared with other equally
complex diseases, where major therapeutic advances and remission-inducing strategies have been made [38].
By recruiting patients across the spectrum of obstructive lung disease, and by using both clinical features
and known and emerging biomarkers to identify phenotypes and endotypes associated with differential
outcomes, NOVELTY aims to support a paradigm shift towards personalised healthcare.
The strengths of NOVELTY include its size and geographical scope, patient enrolment from active primary
and secondary clinical practices (including patients not typically included in clinical or mechanistic trials),
inclusion of patients across obstructive lung disease and physician-assigned severities, broad inclusion and
minimal exclusion criteria, the wide range of data collected (including samples for biobanking), use of the
same parameters across diagnostic labels, long follow up and both retrospective and prospective data
collection. By involving 19 countries and approximately 12000 patients worldwide, NOVELTY will also
allow high-precision comparisons between regions beyond the scope of most studies.
It is anticipated that recruiting patients across all disease severities, and patients not normally involved in
clinical trials, including those with comorbidities, will result in a study population that samples real-world
clinical practice. In contrast to randomised clinical trials that exclude up to approximately 95% of patients [16],
⩾95% of patients ⩾18 years of age with asthma and/or COPD should be eligible for NOVELTY.
Stratification of recruitment in each country, aiming for similar numbers across physician-assigned
diagnosis/severity categories, should allow sufficient sample sizes for groups such as severe asthma, which
constitutes only 3–10% of the general asthma population [39]. By including patients with newly diagnosed
disease, there is a greater chance to identify underlying pathobiological mechanisms before the effects of
further ageing and environmental influences have been superimposed [40]. Given the global challenges
with under-diagnosis of chronic diseases such as asthma and COPD [41], and that NOVELTY aims to
describe patient characteristics that could lead to a re-classification of obstructive lung disease, enrolment
will not be limited to patients with an established diagnosis but will also include those with respiratory
symptoms consistent with either disease, for whom a diagnosis has not yet been made.
In order to identify clinically meaningful phenotypic groups and endotypes associated with differential
outcomes, “open” hypothesis-free bioinformatics approaches will be used on longitudinal data. Previously,
cluster analyses to define phenotypes have typically used cross-sectional baseline data, then compared
outcomes between these clusters [42, 43]. While such analyses will be performed and findings compared
with those from large cross-sectional studies such as U-BIOPRED, COPDGene and SPIROMICS, a unique
feature of NOVELTY is that we will also identify groups of patients by clinically important outcomes over
time (including trajectory of symptoms, clinical evolution (i.e. clinical progression or remission) and
HCU), then look back to identify any baseline characteristics by which these groups can be predicted.
Limitations of NOVELTY include that patient recruitment via clinical practice may bias selection towards
those making frequent healthcare visits; HCPs may not enrol patients due to resource or time constraints
or be tempted to recruit patients with less complex disease. In addition, physicians may be collecting more
information on patient characteristics and lung function than they normally would, which could influence
treatment decisions. However, the strategy of comparing patient characteristics from NOVELTY with EMR
data from the same practice will allow objective validation and further strengthen the generalisability of the
project findings to patients in usual care. As described above, there may initially be limited opportunities
for external validation of NOVELTY findings because of a paucity of multinational studies that have
recruited patients with asthma and/or COPD, and that have used the same tools regardless of diagnostic
label. However, the opportunities for future external validation will be enhanced by publication of the set
of NOVELTY tools (including diagnosis-agnostic PROs) so that they can be included in future
epidemiologic, clinical and mechanistic studies.
In conclusion, NOVELTY is a very large, worldwide and innovative observational study that goes beyond the
scope of many other respiratory observational studies. It is enhanced by broad patient recruitment, a
comprehensive longitudinal statistical analysis, PROs, and collection of biospecimens and physiological data for
biomarker analysis and molecular endotyping. Results from the study may allow much more precise patient
classification according to clinical outcomes and biomarker profiles over time and support the development of
novel therapies and a personalised approach across obstructive lung disease. These rich data will augment our
understanding of obstructive lung disease, with the ultimate aim of improving patient outcomes.
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